FAQ on Polyrizon Ltd.'s $17M Private Placement and Its Biotech Innovations

What is Polyrizon Ltd. known for?

Polyrizon Ltd. is a biotech company specializing in the development of innovative intranasal hydrogels designed to form a protective barrier in the nasal cavity against viruses and allergens.

How much did Polyrizon Ltd. raise in its recent private placement?

Polyrizon Ltd. raised approximately $17.0 million in its recent private placement.

What will Polyrizon Ltd. use the funds from the private placement for?

The company intends to use the net proceeds from the offering, together with its existing cash, for general corporate purposes and working capital.

Who acted as the exclusive placement agent for Polyrizon’s private placement?

Aegis Capital Corp. acted as the exclusive placement agent for the private placement.

What is Polyrizon’s proprietary technology called?

Polyrizon’s proprietary technology is called Capture and Contain TM (C&C) hydrogel technology, aimed at creating a biological mask with a shield containment barrier in the nasal cavity.

Where can I find more information about Polyrizon Ltd.?

For more information about Polyrizon Ltd., please visit their official website at https://polyrizon-biotech.com.

What is the significance of Polyrizon’s private placement?

The private placement signifies a crucial funding milestone for Polyrizon, enabling further development of its innovative hydrogel technology and supporting its general corporate and working capital needs.

Who were the legal counsels involved in the private placement?

Greenberg Traurig, P.A. acted as counsel to Polyrizon, and Kaufman & Canoles, P.C. acted as counsel to Aegis Capital Corp.

What is the potential application of Polyrizon’s technology?

Polyrizon’s technology has potential applications in providing a barrier against viruses and allergens in the nasal cavity and in the intranasal delivery of drugs.